.jpg)
Orca's cell therapy trounces traditional care in blood cancer phase 3, swimming into space's 'holy grail'
In a late-stage trial of patients with multiple types of blood cancers, Orca Bio’s allogeneic T-cell immunotherapy doubled the rate at which patients survived without developing chronic graft-versus-host disease. Investigators compared the cell therapy against conventional allogeneic stem cell transplants.
In a late-stage trial of patients with multiple types of blood cancers, Orca Bio’s allogeneic T-cell immunotherapy doubled the rate at which patients survived without developing chronic graft-versus-host disease. Investigators compared the cell therapy against conventional allogeneic stem cell transplants.
